Effects of the Pharmaceutical Industry on the Health Care System
The current model of the pharmaceutical market creates a conflict between the competing interests of the patients and the pharmaceutical industry where the increasing market expansion and profitability of the industry is happening at the cost of patients’ ability to receive the most appropriate and effective treatment. The interests of the Pharmaceutical industry outcompeted the interests of patients and public health providers by the increased integration and resulting influence of the pharmaceutical industry in all aspects of healthcare and medical research. This increased influence of the pharmaceutical companies allowed them to expand rapidly through mainly two complementary processes: Disease-mongering and “pharmaceuticalisation”. Disease-mongering is described as efforts to enlarge the market of a treatment by either narrowing the definition of health so more people seek medical intervention or by broadening the definition of disease so milder symptoms and health conditions now require medical intervention. Pharmaceuticalisation is the increasing belief of individuals and healthcare providers that the best method of treating most ailments is only through a pharmaceutical solution. (Applbaum 84-102) These two processes have led to an environment where the prescription of a specific treatment does not depend on how effective it is but rather how well the manufacturer of the treatment has marketed their brand in comparison to other treatments. The total spending on pharmaceuticals across OECD countries is estimated to be more than 700 billion USD in 2009. (OECD 7.4) This incredible amount of revenue and wealth gives the pharmaceutical industry an equally vast amount of power and ability to influence.
Competition in the pharmaceutical industry
Free-market advocates claim that competition results in the best possible outcome for all parties involved. Perfect competition is claimed to lead to the best product for the consumer and it’s also supposed to
Competition in the pharmaceutical industry
Free-market advocates claim that competition results in the best possible outcome for all parties involved. Perfect competition is claimed to lead to the best product for the consumer and it’s also supposed to
Cited: Angell, Marcia. "Excess in the Pharmaceutical Industry." CMAJ : Canadian Medical Association journal = journal de l 'Association medicale canadienne 171.12 (2004): 1451-3. Web. Applbaum, Kalman. “Marketing Global Health Care: The Practices of Big Pharma.” The Socialist Register, 2010 Morbid Symptoms: Health Under Capitalism, Leo Panitch and Colin Leys, (eds.). (2010). 84-102. Web. Baker, Dean. "The Benefits and Savings from Publicly Funded Clinical Trials of Prescription Drugs." International journal of health services : planning, administration, evaluation 38.4 (2008): 731-50. Web. Bankert, Elizabeth A., and Robert J. Amdur. Institutional Review Board: Management and Function. Sudbury, Mass: Jones and Bartlett, 2006. Web. Batt, Sharon, and Canadian Women 's Health Network. Marching to Different Drummers: Health Advocacy Groups in Canada and Funding from the Pharmaceutical Industry. Winnipeg, Man.: Canadian Women 's Health Network, 2005. Web. Finucane, Thomas E., and Chad E. Boult. "Association of Funding and Findings of Pharmaceutical Research at a Meeting of a Medical Professional Society." The American Journal of Medicine 117.11 (2004): 842-5. Web. Gemperli, Marcel P. "Rethinking the Role of the Learned Intermediary: The Effect of Direct-to-Consumer Advertising on Litigation." JAMA: The Journal of the American Medical Association 284.17 (2000): 2241-. Web. Landefeld, C. Seth. "Commercial Support and Bias in Pharmaceutical Research." The American Journal of Medicine 117.11 (2004): 876-8. Web. Lexchin, Joel. "Intellectual Property Rights and the Canadian Pharmaceutical Marketplace: Where do we Go from here?" International journal of health services : planning, administration, evaluation 35.2 (2005): 237-56. Web. Macilwain, Colin. "NIH Urged to Cap Profits made on Publicly Funded Research." Nature 406.6791 (2000): 5-. Web. MILES, STEVEN, and Jeff Stier. "Does Pharmaceutical Industry Funding Bias Research?" Clinical Psychiatry News 37.4 (2009): 9-. Web. Mintzes, Barbara. "Disease Mongering in Drug Promotion: Do Governments have a Regulatory Role?" PLoS Medicine 3.4 (2006): e198. Web. OECD. Health at a Glance 2011. Organisation for Economic Co-operation and Development, 2011. Web. Ostry, A. S. "International Trade Regulation and Publicly Funded Health Care in Canada." International journal of health services : planning, administration, evaluation 31.3 (2001): 475-80. Web. Stokamer, Charlene L. "Pharmaceutical Gift Giving: Analysis of an Ethical Dilemma." The Journal of nursing administration 33.1 (2003): 48. Web. Turner, Erick H., et al. "Selective Publication of Antidepressant Trials and its Influence on Apparent Efficacy." The New England journal of medicine 358.3 (2008): 252-60. Web.